Aerovate Therapeutics (AVTE) Expected to Announce Earnings on Monday

Aerovate Therapeutics (NASDAQ:AVTE) will likely be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Aerovate Therapeutics to post earnings of ($0.40) per share for the quarter.

Aerovate Therapeutics Trading Up 0.8 %

AVTE opened at $2.52 on Friday. The stock has a market cap of $72.77 million, a PE ratio of -0.84 and a beta of 1.01. Aerovate Therapeutics has a 1 year low of $1.25 and a 1 year high of $32.42. The stock’s 50 day simple moving average is $2.49 and its 200-day simple moving average is $2.41.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.